Drug Shortage Report for HALOPERIDOL INJECTION, USP
Report ID | 163518 |
Drug Identification Number | 02406411 |
Brand name | HALOPERIDOL INJECTION, USP |
Common or Proper name | HALOPERIDOL INJECTION, USP |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | HALOPERIDOL |
Strength(s) | 5MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
Packaging size | 1 ml |
ATC code | N05AD |
ATC description | ANTIPSYCHOTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-07-01 |
Actual start date | 2022-07-01 |
Estimated end date | 2022-09-05 |
Actual end date | 2022-09-13 |
Shortage status | Resolved |
Updated date | 2022-09-14 |
Company comments | Fresenius Kabi Canada regrets to advise that due to production and shipping delays, we will be encountering a supply interruption on our Haloperidol Injection, USP 5 mg/mL MD Vial 1 mL effective July 1, 2022 until Sep 5, 2022 |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2022-09-14 | English | Compare |
v7 | 2022-09-12 | French | Compare |
v6 | 2022-09-12 | English | Compare |
v5 | 2022-08-21 | French | Compare |
v4 | 2022-08-21 | English | Compare |
v3 | 2022-07-02 | English | Compare |
v2 | 2022-06-27 | French | Compare |
v1 | 2022-06-27 | English | Compare |
Showing 1 to 8 of 8